Balancing Efficacy and Quality of Life in HR-Positive, HER2-Negative Advanced Breast Cancer

Dr. Seth Wander and Dr. Jason Mouabbi discuss the importance of evaluating both clinical outcomes and patient experience when selecting treatment strategies for HR-positive, HER2-negative advanced breast cancer. Dr. Wander reviews patient-reported outcomes from the SERENA-6 study, highlighting considerations around tolerability, symptom burden, and delaying disease progression when adapting therapy based on ESR1 mutation detection. The experts discuss how maintaining quality of life is a critical consideration in the metastatic setting, where treatment goals include extending disease control while preserving patients’ daily activities and overall well-being. Dr. Mouabbi emphasizes the importance of considering patient-centered outcomes, including pain, functioning, and quality of life, alongside traditional efficacy measures. The discussion reinforces the need for individualized treatment decisions that account for both therapeutic benefit and patient experience in HR-positive, HER2-negative advanced breast cancer management.